Aconiti Brachypodi Radix, belonging to the genus of Aconitum (Family Ranunculaceae), are used clinically as anti-rheumatic, anti-inflammatory and anti-nociceptive in traditional medicine of China. However, its mechanism and influence on nociceptive threshold are unknown and need further investigation. The analgesic effects of ethanolic extract of Aconiti Brachypodi Radix (EABR) were thus studied in vivo and in vitro. Three pain models in mice were used to assess the effect of EABR on nociceptive threshold. In vitro study was conducted to clarify the modulation of the extract on the tetrodotoxin-sensitive (TTX-S) sodium currents in rat's dorsal root ganglion (DRG) neurons using whole-cell patch clamp technique. The results showed that EABR (5-20 mg/kg, i.g.) could produce dose-dependent analgesic effect on hot-plate tests as well as writhing response induced by acetic acid. In addition, administration of 2.5-10 mg/kg EABR (i.g.) caused significant decrease in pain responses in the first and second phases of formalin test without altering the PGE 2 production in the hind paw of the mice. Moreover, EABR (10 μg/ml -1 mg/ml) could suppress TTX-S voltage-gated sodium currents in a dose-dependent way, indicating the underlying electrophysiological mechanism of the analgesic effect of the folk plant medicine. Collectively, our results indicated that EABR has analgesic property in three pain models and useful influence on TTX-S sodium currents in DRG neurons, suggesting that the interference with pain messages caused by the modulation of EABR on TTX-S sodium currents in DRG neurones may explain some of its analgesic effect.
Effect of EABR on writhing response induced by acetic acid
showed that lower dose of EABR (2.5 mg/kg) had a tendency of inhibition on the number of writhing for 20 min, but it had no significance compared to the Control (P > 0.05). EABR (5 mg/kg) could significantly inhibit the writhing response induced by an intraperitoneal injection of acetic acid in mice. The positive control drug, aspirin (200 mg/kg), also significantly inhibited the writhing response (Table 1) . More obvious effect of EABR were observed at doses of 10 and 20 mg/kg. But there was no significant difference between 10 and 20 mg/kg groups (P > 0.05). However, administration of vehicle did not show any antinociceptive response. Data are mean ± S.E.M. *P < 0.05, ** P < 0.01, significantly different versus control group. # P < 0.05, ## P < 0.01, significantly different versus positive control group. 
Effect of EABR on hind paw licking response and PGE 2 release in hind paw of mice induced by formalin
Results are shown in Table 2 . EABR (2.5-10 mg/kg) produced a dose-dependent inhibition on formalin-induced biphasic pain responses (neurogenic and inflammatory pain) in mice. The analgesic effects seemed to be more obvious As shown in Figure 2 , the PGE 2 production increased significantly in hind paw of mice induced by formalin compared with control. The positive control drug, aspirin (200 mg/kg), significantly decreased the PGE 2 production. On the other hand, 1 -10 mg/ml EABR could not obviously inhibit the PGE 2 release. 
Effects of EABR on TTX-S sodium peak currents in DRG neurons
At a holding potential of -80 mV, the control TTX-S sodium currents in DRG neurons were recorded. The cell was then exposed to drug for 1 s and the pulse protocol was repeated. The influence of EABR (0.01 -8 mg/ml) on TTX-S sodium peak current amplitudes were calculated according to the records in the absence and presence of drug. All the results are illustrated by the numerical data in Figures 3 -4 . The result indicated that lower concentrations of EABR (0.01 -1 mg/ml) could reduce TTX-S sodium peak current amplitudes to some extent. On the contrary, it showed opposite effect at the dosages above 2 mg/ml. 2 -8 mg/ml EABD dose-dependently increased the TTX-S sodium peak current amplitudes. (Figure   4 ). (Singhuber et al., 2009) . Our study also observed that the analgesic effects of EABR were within a rather small therapeutic range in vivo and in vitro. It would display obvious toxicity at the doses above 20 mg/kg in vivo and 2 mg/ml in vitro. In the preliminary test, some of the animals accepted EABR above the dose of 20 mg/kg showed central depression, body stretching or even death (Data not shown). Compared to the lower dosage group, EABD (2-8 mg/ml) displayed obvious excitability on the TTX-S sodium currents, demonstrating potential toxicity on neuron cells when largely used, suggesting a toxic reaction of higher doses of EABD. So, it's very important to control the therapeutic dosage of the medicine in clinical use. The toxic-effect relationship may be interesting and needs to be further confirmed.
Taken together, the present study demonstrated that EABR has analgesic effects within a small therapeutic range, probably via a mechanism involving Na + channels. The findings of this study suggested that EABR has a potential to be developed into an effective drug for the prevention and treatment of various pain syndromes if correctly employed.
